Second-line therapy for multiple myeloma: Where we are now? Presented ByDr Francesca Gay, University of Torino, Italy ConferenceEMN 2024 23 April, 2024 11:56
The state of toxicities for immunotherapy for multiple myeloma Presented ByDr Alfred Garfall, University of Pennsylvania, PA, USA ConferenceEMN 2024 23 April, 2024 11:39
Early multiple myeloma: where are immunotherapies headed? Presented ByDr Elias K. Mai, University Hospital Heidelberg, Germany ConferenceEMN 2024 23 April, 2024 11:34
How does resistance arise for immunotherapy in relapsed/refractory multiple myeloma? Presented ByDr Nizar Bahlis, University of Calgary, Canada ConferenceEMN2024 23 April, 2024 11:27
Functional imaging to complement bone marrow MRD in multiple myeloma Presented ByDr Elena Zamagni, Bologna University, Italy ConferenceEMN 2024 22 April, 2024 13:04
Mass spectrometry detection of MRD for patients with multiple myeloma Presented ByDr Joannes F. M. Jacobs, Radboud University Medical Center, the Netherlands ConferenceEMN 2024 22 April, 2024 13:02
Is MRD testing ready for prime time in multiple myeloma? Presented ByProf. Edward A. Stadtmauer, University of Pennsylvania, PA, USA ConferenceEMN 2024 22 April, 2024 12:59
Managing transplant-ineligible elderly and frail patients with multiple myeloma Presented ByDr Salomon Manier, University of Lille, France ConferenceEMN 2024 22 April, 2024 12:57
Treatment should be tailored to frailty status in patients with transplant-ineligible newly diagnosed multiple myeloma Presented ByDr Sara Bringhen, University of Torino, Italy ConferenceEMN 2024 22 April, 2024 12:53
Interview: Advancing Myeloma Care ExpertProf. Monique Minnema, UMC Utrecht, the Netherlands 19 March, 2024 14:42
KdD outperforms Kd in R/R MM also in participants with poor renal function Presented ByProf. Meletios Dimopoulos, University of Athens, Greece TrialPhase 3, CANDOR ConferenceASH 2023 7 February, 2024 14:58
IsKia: Novel treatment regimen for MM delivers high MRD-negativity rates Presented ByProf. Francesca Gay, University of Torino, Italy TrialPhase 3, IsKia ConferenceASH 2023 7 February, 2024 14:57
Novel standard-of-care in newly diagnosed MM Presented ByProf. Pieter Sonneveld, Erasmus MC, the Netherlands TrialPhase 3, Perseus ConferenceASH 2023 6 February, 2024 16:34
Can we combine teclistamab and nirogacestat for the treatment of RRMM? Presented ByDr Jeffrey Matous, Colorado Blood Cancer Institute, Colorado, USA TrialPhase 1, MajesTEC-2 ConferenceEHA 2023 2 August, 2023 15:21
Encouraging results for low-dose belantamab mafodotin plus nirogacestat in patients with RRMM Presented ByProf. Sebastian Grosicki, Medical University of Silesia, Poland TrialPhase 1/2, DREAMM 5 ConferenceEHA 2023 2 August, 2023 15:15
CARTITUDE-4: Cilta-cel meets expectations in lenalidomide-refractory MM Presented ByDr Hermann Einsele, University of Würzburg, Germany TrialPhase 3, CARTITUDE-4 ConferenceEHA 2023 2 August, 2023 15:08
Next-generation cell therapies for cancer: CAR-NK cells Presented ByDr Katy Rezvani, MD Anderson Cancer Center, TX, USA ConferenceEBMT 2023 15 June, 2023 17:20
Ide-cel superior to standard therapies in triple-class exposed RRMM Presented ByDr Paula Rodríguez-Otero, Clinica Universidad de Navarra, Spain TrialPhase 3, KarMMa-3 ConferenceEBMT 2023 15 June, 2023 16:48
ASCT or CAR T cell as first-line therapy for MM? Presented ByProf. Salomon Manier, Lille University Hospital, France TrialPhase 3, CARTITUDE-6 ConferenceEBMT 2023 14 June, 2023 20:23
DETERMINATION: Does one size fit all in multiple myeloma? Presented ByDr Hani Hassoun, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 3, DETERMINATION ConferenceEBMT 2023 14 June, 2023 20:14
Dexamethasone and Pomalidomide in combination with Elotuzumab for RRMM TrialPhase 2, ELOQUENT-3 17 April, 2023 14:28
CAR T cells rise to the front in multiple myeloma ExpertDr Sergio Giralt, Memorial Sloan Kettering Cancer Center, USA TrialPhase 3, KarMMa-3 17 April, 2023 12:45
Talquetamab further investigated in heavily pre-treated MM after promising phase 2 data Presented ByProf. Ajai Chari, Mount Sinai School of Medicine, NY, USA TrialPhase 1/2, MonumenTAL-1 ConferenceASH 2022 20 February, 2023 12:19
Promising results of elranatamab for MM in phase 2 MagnetisMM-3 trial Presented ByProf. Nizar Bahlis, University of Calgary, Canada TrialPhase 2, MagnetisMM-3 ConferenceASH 2022 20 February, 2023 12:09
Deep and durable responses for quadruple therapy in smouldering MM Presented ByProf. Shaji Kumar, Mayo Clinic, MN, USA TrialPhase 2, ASCENT ConferenceASH 2022 20 February, 2023 12:04
Ultra-sensitive MRD assessment in MM with BloodFlow Presented ByDr Laura Notarfranchi, University of Parma, Italy TrialPhase 3, GEM2014MAIN ConferenceASH 2022 20 February, 2023 11:55
CAR-Hematotox score proves useful in relapsed/refractory MM Presented ByDr Kai Rejeski, LMU Munich, Germany ConferenceASH 2022 20 February, 2023 11:52
Head-to-head: VMP versus Rd in transplant-ineligible MM Presented ByDr Sara Bringhen, Università degli Studi di Torino, Italy TrialPhase 4, REAL-MM ConferenceASH 2022 20 February, 2023 11:47
Autologous stem cell transplantation plus RVd improves PFS in multiple myeloma Presented ByProf. Paul Richardson, Harvard Medical School, MA, USA TrialPhase 3, DETERMINATION ConferenceASCO 2022 5 August, 2022 14:33
Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma Presented ByProf. Juan Du, Shanghai Chang Zheng Hospital, China ConferenceASCO 2022 5 August, 2022 14:24
Post-transplant carfilzomib, lenalidomide, and dexamethasone outperforms post-transplant lenalidomide in multiple myeloma Presented ByDr Dominik Dytfeld, Poznan University of Medical Sciences, Poland TrialPhase 3, ATLAS ConferenceEHA 2022 1 July, 2022 11:24
Triplet therapy plus early ASCT improves PFS in newly diagnosed multiple myeloma versus triplet therapy alone Presented ByDr Paul Richardson, Dana-Farber Cancer Institute, MA, USA TrialPhase 3, DETERMINATION ConferenceEHA 2022 1 July, 2022 11:21
Blood cancer patients show strong T-cell response to COVID vaccines ConferenceASCO 2022 7 June, 2022 19:23
Teclistamab yields high response rate in relapsed multiple myeloma, carries high risk of side effects Journal The New England Journal of Medicine 6 June, 2022 18:17
GRIFFIN: Sustained responses of daratumumab plus RVd in MM Presented ByDr Jacob Laubach, Dana-Farber Cancer Institute, MA, USA TrialPhase 2, GRIFFIN ConferenceASH 2021 4 February, 2022 11:30
MajesTEC-1: Teclistamab efficacious in heavily pre-treated MM Presented ByProf. Philippe Moreau, University Hospital of Nantes, France TrialPhase 1/2, MajesTEC-1 ConferenceASH 2021 4 February, 2022 11:26
iStopMM: Smouldering MM highly prevalent in general population Presented ByDr Sigrún Thorsteinsdóttir, University of Iceland, Iceland TrialiStopMM ConferenceASH 2021 4 February, 2022 11:25
Mechanisms of D-KRd treatment failure in MM identified Presented ByDr Eileen Boyle, NYU Langone Health, NY, USA ConferenceASH 2021 4 February, 2022 11:22
TRIMM-2: Favourable results of talquetamab plus daratumumab for MM Presented ByDr Ajai Chari, Mount Sinai School of Medicine, NY, USA TrialPhase 1, TRIMM-2 ConferenceASH 2021 4 February, 2022 11:16
ASH 2021 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceASH 2021 4 January, 2022 08:00
CAR-T cell therapy for multiple myeloma may lead to Parkinson’s-like symptoms JournalNature Medicine 15 December, 2021 16:39
Some young people who undergo HCT retain ability to conceive JournalHuman Reproduction 20 October, 2021 19:04
Limited evidence supports many hematopoietic stem cell transplant guidelines JournalJAMA Network Open 19 October, 2021 23:16
Triplet therapy for high-risk smoldering myeloma may delay progression to overt disease JournalJAMA Oncology 27 September, 2021 15:23
Immune therapy of multiple myeloma Presented ByProf. Noopur Raje, Massachusetts General Cancer Center, USA TrialKarMMA; CARTITUDE-1; UNIVERSAL ConferenceEHA 2021 5 August, 2021 14:49
MAIA results confirm superior efficacy of daratumumab with standard-of-care Presented ByProf. Thierry Facon, University of Lille, France TrialPhase 3, MAIA ConferenceEHA 2021 5 August, 2021 14:46
Different IV bisphosphonates dosing tied to similar skeletal event rates in multiple myeloma JournalJAMA Network Open 30 July, 2021 22:36
Multiple-myeloma patients may not mount adequate response to COVID vaccine JournalCancer Cell 2 July, 2021 16:31
Adding daratumumab to triple therapy might help patients with newly diagnosed multiple myeloma JournalJAMA Oncology 21 April, 2021 15:56
Some older people with multiple myeloma can safely skip long-term steroids JournalBlood 8 April, 2021 17:35
CAR-T-cell multiple myeloma treatment effective in early trial JournalThe New England Journal of Medicine 24 February, 2021 23:00
Validation of MY-RADS response assessment category criteria Presented ByDr Angelo Belotti, ASST Spedali Civili di Brescia, Italy ConferenceASH 2020 18 February, 2021 10:43
High symptom burden in transplant-ineligible patients with newly diagnosed MM Presented ByDr Hira Mian, McMaster University, Canada ConferenceASH 2020 18 February, 2021 10:42
Added value of ixazomib to lenalidomide plus dexamethasone in transplant-ineligible newly diagnosed MM Presented ByProf. Thierry Facon, University Hospital Lille, France TrialPhase 3, TOURMALINE-MM2 ConferenceASH 2020 18 February, 2021 10:37
Survival of transplant-eligible newly diagnosed MM in FORTE trial Presented ByDr Francesca Gay, GIMEMA, European Myeloma Network, Italy TrialPhase 2, FORTE ConferenceASH 2020 18 February, 2021 10:35
Better survival with upfront autoSCT versus bortezomib-based intensification Presented ByProf. Michele Cavo, University of Bologna, Italy TrialPhase 3, EMN02/HO95 ConferenceASH 2020 18 February, 2021 10:29
Subcutaneous daratumumab plus pomalidomide and dexamethasone in R/R MM Presented ByProf. Meletios Dimopoulos, University of Athens, Greece TrialPhase 3, APOLLO ConferenceASH 2020 18 February, 2021 10:26
Melflufen well tolerated with encouraging activity in heavily pretreated R/R MM Presented ByDr Enrique Ocio, University Hospital Marqués de Valdecilla, Spain TrialPhase 1/2, ANCHOR (OP-104) ConferenceASH 2020 18 February, 2021 10:22
Initial data of FcRH5/CD3 T-cell-engaging bispecific antibody Presented ByDr Adam Cohen, University of Pennsylvania, Philadelphia, USA TrialPhase 1, GO39775 ConferenceASH 2020 18 February, 2021 10:20
Deep and durable responses with ide-cel in RRMM Presented ByDr Yi Lin, Mayo Clinic, Minnesota, USA TrialPhase 1, CRB-401 ConferenceASH 2020 18 February, 2021 10:17
Assessing measurable residual disease tied to better outcome in multiple myeloma ConferenceAmerican Society of Hematology (ASH) Annual Meeting 21 December, 2020 20:46
Origins of blood cancer traced to early childhood, decades before diagnosis ConferenceAmerican Society of Hematology 2020 Annual Meeting 17 December, 2020 17:42
Venetoclax boosts progression-free survival in myeloma patients, but may cause more deaths JournalLancet Oncology 11 November, 2020 17:52
Isatuximab triplet improves PFS in R/R MM Presented ByProf. Philippe Moreau, University Hospital of Nantes, France TrialPhase 3, IKEMA ConferenceEHA 2020 9 September, 2020 10:26
Initial results from CAR-T cell therapy in MM: KarMMa Presented ByProf. Jesús San Miguel, University of Navarra, Spain ConferenceEHA 2020 9 September, 2020 10:19
Higher risk of severe COVID-19 seen in people with blood cancers JournalThe Lancet Oncology 1 September, 2020 18:28
Carfilzomib: no PFS benefit for multiple myeloma Presented ByProf. Shaji K. Kumar, Mayo Clinica, MN, USA TrialPhase 3, ENDURANCE (E1A11) ConferenceASCO 2020 28 August, 2020 16:00
Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma Presented ByDr Christine Chen, Princess Margaret Cancer Centre, University of Toronto, Canada TrialMM-003, STOMP ConferenceASH 2019 5 March, 2020 22:59
BCMA-targeted CAR T therapy yields 100% response in relapsed/refractory MM Presented ByDr Deepu Madduri, Mount Sinai Medical Center, USA TrialPhase 1/2, CARTITUDE-1 ConferenceASH 2019 5 March, 2020 20:29
Adding daratumumab to carfilzomib/dexamethasone prolongs PFS and OS in R/R MM Presented ByProf. Saad Usmani, UNC-Chapel Hill School of Medicine, USA TrialPhase 3, CANDOR ConferenceASH 2019 5 March, 2020 19:49
Anti-BCMA/anti-CD38 in refractory multiple myeloma Presented ByProf. Yu Hu, Huazhong University of Science and Technology, China ConferenceASH 2019 5 March, 2020 16:31
ALCYONE: New overall survival results for myeloma Presented ByDr Maria Victoria Mateos, University Hospital of Salamanca, Spain TrialPhase 3, ALCYONE ConferenceASH 2019 5 March, 2020 16:16
Off-the-shelf natural killer cells Presented ByDr Jode Goodridge, Fate Therapeutics, USA ConferenceASH 2019 5 March, 2020 09:38
CASSIOPEIA trial: Phase 3 results of daratumumab + bortezomib/thalidomide/dexamethasone in multiple myeloma Presented ByProf. Phillippe Moreau, University Hospital of Nantes, France TrialPhase 3, CASSIOPEIA ConferenceEHA 2019 9 August, 2019 23:30
Chimeric antigen receptor T cell therapy in multiple myeloma Presented ByProf. Hermann Einsele, University of Würzburg, Germany ConferenceEHA 2019 9 August, 2019 22:34
Higher levels of treatment satisfaction without compromising efficacy: subcutaneous daratumumab in RRMM Presented ByProf. María-Victoria Mateos , University of Salamanca, Spain TrialPhase 3, COLUMBA ConferenceEHA 2019 9 August, 2019 21:36
Adding isatuximab to pomalidomide and dexamethasone improves PFS and ORR in RRMM Presented ByProf. Michel Attal, University Institute Cancer Toulouse Oncopole, France TrialPhase 3, ICARIA-MM ConferenceEHA 2019 9 August, 2019 20:38
Venetoclax for multiple myeloma: effective but some safety concerns Presented ByDr Shaji Kumar, Mayo Clinic, USA TrialPhase 3, BELLINI ConferenceEHA 2019 9 August, 2019 09:42
Daratumumab a promising treatment option for transplant-eligible multiple myeloma Presented ByDr Philippe Moreau, University Hospital Hôtel-Dieu, France TrialPhase 3, CASSIOPEIA ConferenceASCO 2019 15 July, 2019 23:14
Anti-CD38 antibody isatuximab improves treatment response, PFS in R/R multiple myeloma Presented ByDr Paul G. Richardson, Dana-Farber Cancer Institute/Harvard Medical School, USA TrialPhase 2, ICARIA-MM ConferenceASCO 2019 15 July, 2019 13:53